Table 1.
Epidemiological variables and infection types
| Total n = 182 | E. faecalis n = 144 | E. faecium n = 38 | |
|---|---|---|---|
| Age, mean (SD), years | 64.6 (18.2) | 65.0 (19.3) | 64.8 (13.5) |
| Male sex n, (%) | 114 (62.6) | 89 (61.8) | 25 (65.8) |
| Type of infection n, (%) | |||
| Intra-peritoneal infections | 74 (40.7) | 59 (41.0) | 15 (39.5) |
| Intra-peritoneal infections after liver transplantation | 13 (7.1) | 4 (2.8) | 9 (23.7) |
| Urinary tract infections | 29 (15.9) | 29 (20.1) | 0 (0.0) |
| Febrile neutropenia | 16 (8.8) | 11 (7.6) | 5 (13.2) |
| Bone and soft-tissue infections | 17 (9.3) | 14 (9.7) | 3 (7.9) |
| Blood stream infections | 20 (11.0) | 15 (10.4) | 5 (13.2) |
| Pulmonary infections | 10 (5.5) | 10 (6.9) | 0 (0.0) |
| Vascular grafts infections | 3 (1.6) | 2 (1.4) | 1 (2.6) |
| Comorbidity n, (%) | |||
| Cancer and hematologic malignancy | 65 (35.7) | 57 (39.6) | 8 (21.1) |
| Hematologic malignancy | 22 (12.1) | 14 (9.7) | 8 (21.1) |
| Solid organ transplantation | 19 (10.4) | 10 (6.9) | 9 (23.7) |
| Bone marrow and stem cell transplantation | 9 (4.9) | 3 (2.1) | 6 (15.8) |
| Diabetes mellitus | 14 (7.7) | 12 (8.3) | 2 (5.3) |
| Collagen vascular disease | 12 (6.6) | 9 (6.3) | 3 (7.9) |
| Chronic kidney disease | 53 (29.1) | 40 (27.8) | 13 (34.2) |
| Structural abnormality of urinary tract | 22 (12.1) | 21 (14.6) | 1 (2.6) |
| Hemodialysis | 12 (6.6) | 10 (6.9) | 2 (5.3) |
| Antimicrobial therapy n, (%) | |||
| Vancomycin | 48 (26.4) | 26 (18.1) | 22 (57.9) |
| Linezolid | 13 (7.1) | 3 (2.1) | 8 (21.1) |
| Teicoplanin | 14 (7.7) | 6 (4.2) | 8 (21.1) |
| Meropenem | 37 (20.3) | 37 (25.7) | 0 (0.0) |
| Imipenem/cilastatin | 15 (8.2) | 15 (10.4) | 0 (0.0) |
| Biapenem | 2 (1.1) | 2 (1.4) | 0 (0.0) |
| Doripenem | 9 (4.9) | 9 (6.3) | 0 (0.0) |
| Piperacillin | 10 (5.5) | 10 (6.9) | 0 (0.0) |
| Tazobactam/piperacillin | 18 (9.9) | 18 (12.5) | 0 (0.0) |
| Ampicillin | 2 (1.1) | 2 (1.4) | 0 (0.0) |
| Sulbactam/ampicillin | 6 (3.3) | 6 (4.2) | 0 (0.0) |
| Levofloxacin | 21 (11.5) | 21 (14.6) | 0 (0.0) |
| Ciprofloxacin | 3 (1.6) | 3 (2.1) | 0 (0.0) |
| Tosufloxacin | 1 (0.5) | 1 (0.7) | 0 (0.0) |
| Combination therapy | 18 (9.9) | 18 (12.5) | 0 (0.0) |
| Culture-positive specimens n, (%) | |||
| Urine | 32 (17.6) | 27 (18.8) | 1 (2.6) |
| Sputum | 9 (4.9) | 9 (6.3) | 0 (0.0) |
| Blood | 37 (20.3) | 25 (17.4) | 6 (15.8) |
| Peritoneal fluid | 32(17.6) | 24 (16.7) | 8 (21.1) |
| Pleural fluid | 1 (0.5) | 1 (0.7) | 0 (0.0) |
| Bile | 16 (8.8) | 10 (6.9) | 6 (15.8) |
| Discharge from abscess | 45(24.7) | 37 (25.7) | 8 (21.1) |
| Central venous catheter tip | 4 (2.2) | 4 (2.8) | 0 (0.0) |
| Throat swab | 5 (2.7) | 4 (2.8) | 1 (2.6) |
| Vascular graft | 3 (1.6) | 2 (1.4) | 1 (2.6) |
| Polymicrobial culture | 83 (45.6) | 70 (48.6) | 13 (34.2) |